France says 'highly probable' EU won't renew AstraZeneca vaccine orders
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[PARIS] The European Union (EU) is very unlikely to renew its Covid-19 vaccine contracts with pharmaceutical company AstraZeneca, a French minister said on Friday.
Denmark this week banned the use of AstraZeneca jabs over blood clot concerns, just as the EU said it was expecting 50 million Pfizer vaccine doses earlier than expected.
No final EU decision had been taken, French Industry Minister Agnes Pannier-Runacher told RMC radio, but "it is highly probable" that no further AstraZeneca doses would be ordered.
The prediction comes after US drugmaker Johnson & Johnson (J&J) said it would delay its European rollout, also over blood clot fears - a major hit for the continent's beleaguered immunisation campaign as several countries battle rising caseloads.
"We have not started talks with Johnson & Johnson or with AstraZeneca for a new contract, but we have started talks with Pfizer/BioNTech and Moderna," Ms Pannier-Runacher said.
The J&J and AstraZeneca setbacks are dampening hopes that mass immunisations will allow a swift exit from a pandemic that has killed close to three million people and ravaged the global economy.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
Meanwhile, 50 million BioNTech/Pfizer doses that were due to arrive in Europe only at the end of 2021 have been brought forward for delivery as soon as this month.
Denmark said Wednesday it would stop using the AstraZeneca vaccine altogether - a European first - despite assurances from the EMA and the World Health Organization that the benefits far outweigh possible risks.
AFP
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
Near sell-out launches in March boost developer sales to 1,300 units after four slow months
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Genting Singapore’s Lim Kok Thay receives S$7.5 million pay package for FY2025